Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
28.19
+1.53 (5.74%)
At close: May 1, 2026, 4:00 PM EDT
27.75
-0.44 (-1.56%)
After-hours: May 1, 2026, 5:06 PM EDT
Forte Biosciences Earnings Call Transcripts
Fiscal Year 2025
-
FB102 demonstrated statistically significant protection against gluten-induced gut inflammation and symptoms in a phase 1B celiac disease trial, with a favorable safety profile. A phase 2 trial is planned, aiming for broader efficacy and longer gluten challenge, with top-line data expected in 2026.